Multiple sclerosis benign

Opinions vary on when to initiate treatment with interferon-p. According to the National Multiple Sclerosis Society, these agents should be considered in patients with relapsing-remitting MS who have had recent relapses. Some neurologists delay treatment until there is a more prolonged history of recurrent relapses, because, in their experience, patients may have a benign early course. 

Most patients with overactive bladder and UUI have no identifiable underlying etiology. In fact, the most common cause of bladder overactivity and UUI is idiopathic. Clearly identifiable risk factors for UUI include normal aging, neurologic disease (including stroke, Parkinson s disease, multiple sclerosis, and spinal cord injury), and bladder outlet obstruction (e.g., due to benign prostatic hyperplasia [BPH] or prostate cancer). 

---